Anemia Explored.

Slides:

Advertisements

Similar presentations

ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.

Advertisements

Understanding Treatment Goals for Patients With Onychomycosis

Locatelli et al. Am J Nephrol 2017;45: (DOI: / )

Volume 88, Issue 5, Pages (November 2015)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD Nupur Gupta, MD, Jay B. Wish, MD American.

Diabetic Dyslipidemia in Practice

Clinical Trials in IBD.

NOACs for Cancer-Associated Thrombosis:

Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

New and Emerging Management Options for Anemia in CKD

New Data on the Safety of SGLT2 Inhibitors

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Cancer Stem Cell Therapies in Gastrointestinal Cancers

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Addressing Iron Deficiency in Chronic HF

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

nAMD: Switching Therapies - what you need to know

Iron Deficiency Anemia

Beyond Statin Therapy.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Clinical Considerations in Evidence-based Management of GIST

Emerging CVOT Data and Clinical Application

The Evolving Role of Immunotherapy in NSCLC

An Update on PCSK9 Inhibitors

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

The future of urate-lowering strategies for gout

Obstacles and Advances in Anemia Management in Patients With CKD

Is RA Treatment Addressing the Real Needs of Patients?

PCSK9 Inhibitors and Cardiovascular Outcomes

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Iron Deficiency Anemia

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD Nupur Gupta, MD, Jay B. Wish, MD American.

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Managing CKD-Associated Anemia in Challenging Patients

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Implications of Emerging Treatments for Beta-Thalassemia

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Managing Age-Related Clinical Issues in Hemophilia

Are We Making Progress in the Management of Huntington Disease?

Iron Deficiency in Heart Failure

Patient Selection for Modern T2D Agents

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.

Reducing Risk for CV Outcomes

Improving Overall Health

The ABCs of Pharmacogenomics in Clinical Practice

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

An Update on PCSK9 Inhibitors

Clinical Considerations in Evidence-based Management of GIST

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

What's New in Oral Combination Therapy for Type 2 Diabetes?

Emerging Advances in Reducing Renal Complications of T2D

Lipids, the Heart, and the Kidney

Challenges and Emerging Solutions in Anemia Management Explored

My PAH Patient.

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Expert Perspectives.

PCSK9 Inhibitors and Real-World Evidence

Risk Stratification in MDS

Presentation transcript:

Anemia Explored

ESA Resistance or Hyporesponsiveness

Evolution of Managing Anemia in CKD

ESA Use in CKD and CV Outcomes Trials

Evolution of Treatment Strategies for Anemia

HIF-PH Inhibitors Under Development*

Erythropoietic Response via HIF

HIF-PHI Mechanism of Action

FDA Boxed Warning on Use of ESAs

Next Big Question Is….

Hypothetical Mechanisms of EPO-Induced Hypertension

How Will HIF-PHIs Impact Patient Reported Outcomes?

Meta-Analysis of HIF-PHI Studies

Potential Clinical Impact of HIF-PHIS

Safety of HIF-PHIs

Role of Iron in Treating Anemia

Clinical Impact of HIF-PHIs on Iron Use

Abbreviations

Abbreviations (cont)